EUVIMEDEUVIMED entdecken
Crossref

Novel quinazoline-based dual EGFR/c-Met inhibitors overcoming drug resistance for the treatment of NSCLC: Design, synthesis and anti-tumor activity

Han Zhang, Wenhui Gan, Dang Fan, Pengwu Zheng, Qiaoli Lv, Qingshan Pan, Wufu Zhu

Bioorganic Chemistry · 2024

DOI: 10.1016/j.bioorg.2023.106938 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2024. Verfasst von Han Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang, Jiangx…. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Antineoplastic Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungAntineoplastic AgentsAnimalsHumansQuinazolinesErbB ReceptorsProtein Kinase InhibitorsApoptosisDrug Resistance, NeoplasmMutationCell Line, TumorG2 Phase Cell Cycle CheckpointsCell Proliferation

Stichwörter der Autor:innen

4-phenoxyquinazolines derivativesDockingDual EGFR/c-Met inhibitorsNSCLC

Substanzen

QuinazolinesErbB ReceptorsProtein Kinase InhibitorsAntineoplastic AgentsEGFR protein, human

Autor:innen und Institutionen

  • Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang, Jiangxi, 330013, PR China.
  • Jiangxi Key Laboratory of Translational Cancer Research, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Clinical Research Center for Cancer, Nanchang, Jiangxi, 330029, PR Ch…
  • Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang, Jiangxi, 330013, PR China. Electronic address: pqs2016@163.com.
  • Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang, Jiangxi, 330013, PR China. Electronic address: zhuwufu-1122@163.com.

Zitieren

APA

Zhang, H., Gan, W., Fan, D., Zheng, P., Lv, Q., Pan, Q., & Zhu, W. (2024). Novel quinazoline-based dual EGFR/c-Met inhibitors overcoming drug resistance for the treatment of NSCLC: Design, synthesis and anti-tumor activity. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2023.106938

Vancouver

Zhang H, Gan W, Fan D, Zheng P, Lv Q, Pan Q, et al. Novel quinazoline-based dual EGFR/c-Met inhibitors overcoming drug resistance for the treatment of NSCLC: Design, synthesis and anti-tumor activity. Bioorganic Chemistry. 2024. doi:10.1016/j.bioorg.2023.106938

BibTeX
@article{Zhang2024,
  author = {Zhang, Han and Gan, Wenhui and Fan, Dang and Zheng, Pengwu and Lv, Qiaoli and Pan, Qingshan and Zhu, Wufu},
  title = {Novel quinazoline-based dual EGFR/c-Met inhibitors overcoming drug resistance for the treatment of NSCLC: Design, synthesis and anti-tumor activity},
  journal = {Bioorganic Chemistry},
  year = {2024},
  doi = {10.1016/j.bioorg.2023.106938}
}
Kostenlos starten →